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Abstract
Paragangliomas (PGLs) are frequently associated with germline mutations in genes involved in energy metabolism. The
purpose of the present study was to assess whether the tumor metabolomic profile of patients with hereditary and
apparently sporadic PGLs enables the distinction of different subtypes of tumors. Twenty-eight unrelated patients with a
histological diagnosis of PGLs were included in the present study. Twelve had germline mutations in SDHx genes (5 SDHB, 7
SDHD), 6 VHL, and 10 were apparently sporadic. Intact tumor samples from these patients (one per patient) were evaluated
with 1H high-resolution magic angle spinning (HRMAS) NMR spectroscopy. SDHx-related tumors were characterized by an
increase in succinate levels in comparison to other tumor subtypes (p = 0.0001 vs VHL and p= 0.000003 vs apparently
sporadic). Furthermore, we found significantly lower values of glutamate in SDHx-related tumors compared to other
subtypes (p = 0.0007 vs VHL and p= 0.003 vs apparently sporadic). Moreover, SDHx-tumors also exhibited lower values of
ATP/ADP/AMP (p = 0.01) compared to VHL. VHL tumors were found to have the highest values of glutathione (GSH)
compared to other tumors. Based on 4 metabolites (succinate, glutamate, GSH, and ATP/ADP/AMP), tumors were accurately
distinguished from the other ones on both 3- and 2-class PLS-DA models. The present study shows that HRMAS NMR
spectroscopy is a very promising method for investigating the metabolomic profile of various PGLs. The present data
suggest the existence of a specific succinate-glutamate hallmark of SDHx PGLs. The relevance of such a metabolomic
hallmark is expected to be very useful in designing novel treatment options as well as improving the diagnosis and follow-
up of these tumors, including metastatic ones.
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Introduction
Paragangliomas (PGLs) are neural crest-derived neuroendocrine
neoplasms arising from chromaffin cells that are located in the
adrenal medulla (also called pheochromocytomas, PHEOs) or
aligned along the para-aortic sympathetic system or from head
and neck or thoracic paraganglia, which often act as chemore-
ceptors. Although most PGLs arise sporadically, PGL susceptibil-
ity genes have been identified in approximately one-third of cases
and in more than 90% of patients with multifocal tumors [1,2].
Hereditary PGLs are frequently associated with germline
mutations in one of the succinate dehydrogenase subunits genes
(collectively named SDHx-related tumors), often in the absence of
positive family history or even with negative biochemistry [3]. This
is in contrast to other hereditary PHEOs/PGLs, in which the
family history is usually very well known and therefore, PHEOs/
PGLs related to these syndromes can be diagnosed early and often
properly and successfully treated.
Moreover, SDHx tumors are considered to be more aggressive,
particularly those with SDHB mutations. Currently there is no
cure, and current therapeutic options are either suboptimal or
short-lasting despite a good initial response [4]. Therefore, any
new information that could bring new insight into the pathogen-
esis of these tumors, their metabolic activities, and proper
monitoring, including early assessment of their therapeutic
responses, is very desirable.
SDH (also called respiratory complex II) is an iron-sulfur
cluster-containing protein composed of 4 subunits that participates
in the tricarboxylic acid (TCA) cycle and electron transport chain
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(ETC). SDH mediates the transfer of two electrons to CoQ during
the oxidation of succinate to fumarate. Inactivation of SDH leads
to the accumulation of succinate. The accumulation of specific
metabolites has been illustrated in different tumor models with
inherited and acquired alterations in enzymes of the TCA cycle,
such as fumarate in cases of fumarate hydroxylase gene mutations
[5] and 2-hydroxyglutarate (2HG) in mutations in one of the 2
isocitrate dehydrogenase genes (IDH1/2) [6]. The accumulation of
these oncometabolites inhibits 2-oxoglutarate (2OG)-dependent
dioxygenases that include EglN (also called PHD) family members,
methylcytosine dioxygenases and JmjC domain-containing histone
demethylases, which induces both pseudohypoxic and hyper-
methylated phenotypes [7–10]. These findings have important
implications for our understanding of tumorigenesis via pseudo-
hypoxia, alteration of epigenetic homeostasis and alteration of the
cellular redox state.
Simultaneous detection of several metabolites (also called
metabolomics) is a fast-growing field, promising to improve our
understanding of cell biology and relating the genetics and
epigenetics to tumor phenotypes. The metabolites (molecular
weight ,1 kDa) can be detected in vitro by gas chromatography-
mass spectrometry (GCMS), liquid chromatography-mass spec-
trometry (LCMS), and nuclear magnetic resonance (NMR)
spectroscopy [11]. Magnetic resonance spectroscopy also enables
in vivo assessment of metabolites (such as 2HG) in the setting of
brain tumors [12]. NMR-based methods are less sensitive but
more reproducible than LCMS for the quantitative assessment of
metabolites.
In recent years, 1H high-resolution magic angle spinning
(HRMAS) NMR spectroscopy has been introduced for ex vivo
characterization of small intact tissue samples (solid-state NMR).
This technique also offers several advantages, such as the
simplicity of sample preparation, the intra- and inter-laboratory
reproducibility, the relatively low cost to perform the technique,
and the availability of major metabolite databases [13]. HRMAS
NMR spectroscopy has been suggested as a promising tool in the
diagnosis and characterization of cancer.
The objective of the present study was to find out whether there
is a specific metabolomic profile in sympathetic SDHx and other
hereditary or apparently sporadic PHEOs/PGLs.
Materials and Methods
Ethics Statement
Data was acquired under regular clinical care conditions, with
Ethics Committee approval obtained for the use of these data for
scientific purposes at Strasbourg, Marseille, and Nancy University
Hospitals. Written informed consent was obtained from all
patients included in the present study.
Tissue samples
Twenty-eight specimens of sympathetic PGLs/PHEOs from 28
unrelated patients who fulfilled the following criteria were
included:
1. Histological diagnosis of PGL/PHEO.
2. Absence of distant metastases within the first year following
surgery.
3. Genetic screening for germline mutations in the SDHB/C/D,
SDHAF2 (including large gene rearrangements of all the SDH
genes), VHL (including large gene rearrangements), RET,
TMEM127, and MAX genes.
4. Tissue specimens collected just after tumor removal and snap-
frozen in liquid nitrogen before storage at 280uC.
The tumors were obtained from 3 different institutions in
France (Strasbourg, Marseille, and Nancy University Hospitals)
and were distributed as follows: 10 sporadic (9 PHEOs, 1
sympathetic PGL), 5 SDHB (2 PHEOs, 3 sympathetic PGLs), 7
SDHD (1 PHEO, 6 sympathetic PGLs), and 6 VHL (3 PHEOs, 3
sympathetic PGLs).
Tissue sample preparation for HRMAS NMR
The amount of tissue used for HRMAS analysis ranged from 15
to 20 mg. For each sample, the percentage of tumor cells in the
total sample of cells and the percentage of necrosis with regard to
the total surface were calculated based on frozen sections using a
mirror sample stored in the tissue bank. Samples containing at
least 30% tumor cells and less than 50% necrosis were used for the
study. Each tissue sample was placed in a 30 mL disposable insert.
10 mL of D2O were added to the rotor to provide a lock frequency
for the NMR spectrometer. The exact weight of the sample used
was determined by weighing the empty insert and the insert
containing the tissue sample. The insert was stored at 280uC and
placed in a 4-mm ZrO2 rotor just before the HRMAS analysis.
HRMAS NMR data acquisition, spectra processing, and
metabolite quantification
1D HRMAS NMR spectra were recorded on a Bruker Avance
III 500 spectrometer operating at a proton frequency of
500.13 MHz, installed at the Pathological Department of
Strasbourg University Hospitals. A one-dimensional (1D) proton
spectrum using a Carr–Purcell–Meiboom–Gill (CPMG) pulse
sequence [14] and 1024 transients was acquired for each serum
sample. Free induction decays were multiplied by an exponential
window function of 0.3 Hz prior to Fourier transformation and
were corrected for phase and baseline distortions using TopSpin
2.1 (Bruker GmbH, Germany). The chemical shift was referenced
to the peak of the methyl proton of L-lactate at 1.33 ppm. In order
to confirm resonance assignments, two-dimensional (2D) homo-
nuclear and heteronuclear experiments were also recorded
immediately after the end of 1D spectra acquisition. Because the
duration of these experiments is long and significant tissue
degradation occurs during NMR acquisition, only a few repre-
sentative samples were analyzed by 2D experiments. A description
of the HRMAS NMR data acquisition and spectra processing has
been previously detailed [13].
In the present study, we focused on four selected metabolites
with a potential key role in tumoral pathophysiology. Accordingly,
succinate, glutamate, glutathione, and energy phosphorylated
compounds were precisely identified and quantified. Catechol-
amines were also measured. The quantification procedure was
based on the pulse length-based concentration measurement
(PULCON) as previously described [13]. Spectra were normalized
according to each sample weight and calibrated using the signal
intensity of a 19.3 nmol reference solution of lactate, scanned
under the same analytical conditions. The peak integral
corresponding to each metabolite’s region was normalized to the
integral of the entire spectrum within the range of 8.65–1 ppm.
Quantification results were expressed as nmol/mg of tissue.
Metabolites were assigned using standard metabolite chemical
shift tables available in the literature [15,16].
Succinate concentrations in tissue samples were estimated by
integrating the area comprised between 2.39 ppm and 2.43 ppm.
The spectral complex previously assigned to ATP/ADP/AMP
[17] was identified on our spectra within the range of 6.07–6.11
and thus integrated to quantify the metabolite amount. The
glutathione and glutamate amounts were measured from the
integral of NMR spectra comprised by 2.93–2.98 ppm and 2.32–
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2.38 ppm, respectively. To measure epinephrine concentrations in
tissue samples, the signal resulting from the N-methyl radical
selected at 2.75 ppm was considered. The 3,4-dihydroxybenzene
groups of both epinephrine and norepinephrine generate a
spectral complex between about 6.85 and 6.98 ppm. The integral
of the region corresponding to the 1H in position no. 5 of the
aromatic ring (IUPAC nomenclature) was selected to quantify the
amount of epinephrine plus norepinephrine in each tissue sample.
Finally, the norepinephrine concentration was obtained by
subtracting epinephrine from the sum of epinephrine and
norepinephrine. The above approach has been previously tested
and confirmed (data not shown) by the quantification NMR
analysis of epinephrine and norepinephrine standard solutions first
separated and subsequently mixed (1/1, v/v). Dopamine could
contribute to peaks in the region between 6.85 and 6.98 ppm.
However, no triplets at 2.85 ppm and 3.22 ppm, which represent
the spectral signature of dopamine, were detected on HRMAS
NMR spectra, suggesting an undetectable amount of dopamine in
the analyzed tissue.
Statistical analysis
As widely suggested [18,19], a combination of principal
component analysis (PCA) and partial least square discriminant
analysis (PLS-DA) was adopted. PCA and PLS-DA analysis were
done including only succinate, glutamate, glutathione, and energy
phosphorylated compounds.
A PCA was performed to evaluate the quality of the data
quickly and to identify possible outliers [20]. Then a PLS-DA was
employed to optimize the separation between groups and to
classify the samples in each of the following 3- or 2-group models:
1. Sporadic vs. SDHx vs. VHL, 2. Sporadic vs. SDHx, 3. Sporadic
vs. VHL, 4. SDHx vs. VHL. Cross-validation was used in each PLS-
DA model to determine the number of components and to avoid
overfitting the data because of the small number of samples. An
extensive cross-validation embedded in a Monte-Carlo resampling
approach was used during the construction of the model in order
to build a confusion matrix that allowed a direct visualization of
the performances of the model in term of classification power
(sensitivity (Se), specificity (Sp), positive predictive value (PPV),
negative predictive value (NPV)) [21,22]. The non-parametric
Mann-Whitney U-test (MWU-test) was utilized for the comparison
of metabolite amounts between groups. The results of tissular
metabolite concentrations are expressed as medians and ranges.
The relationship among the selected metabolites was assessed by
the Spearman nonparametric regression coefficient (R).
SIMCA P (version 11.0, Umetrics AB, Umea˚, Sweden) and
STATISTICA 7 (STATSOFT; www.statsoft.com) packages were
used for statistical data analysis. A p value less than 0.05 was
considered statistically significant.
Results
General findings
Representative 1D HRMAS CPMG spectra of sporadic,
SDHD-, and VHL-related PGLs are presented in Figure 1.
Metabolites such as succinate, glutamate, glutathione (GSH), and
energy phosphorylated compounds (ATP/ADP/AMP) were iden-
tified in 1D spectra, with variable signal intensity according to the
genetic background.
In all the examined tumor samples, no significant spectra
overlap that prevented quantification was found. The quality of
the examined samples was indirectly proven by the lack of signals
arising from both lactate and fatty acids, which are usually
considered hallmarks of tissular necrosis. 2D NMR acquisitions
were used to better characterize the metabolic substrate appearing
on our 1D spectra within the range of 6.07–6.11 ppm and
previously assigned to ATP/ADP/AMP (Fig. 2). In particular, the
results of 2D HRMAS acquisition from one VHL-related PGL
were compared to the widely available NMR spectroscopy
database [16,23]. Our 2D HSQC spectrum was almost superim-
posable to the known reference of ATP. Nevertheless, a slight
chemical shift difference of 0.06 ppm related to the carbon atom
linking the ribosyl ring and the aminopurinine may generate
confusion with inosine triphosphate (ITP). This difference could be
explained by the intratissular pH variability in our samples.
All NMR spectra from the SDHx-related tumors showed very
high levels of succinate compared to sporadic and VHL-related
tumors. On the other hand, apparently sporadic tumors were
characterized by high values of glutamate compared to SDHx-
related PGLs/PHEOs. Finally, VHL-related tumors exhibited
more pronounced ATP/ADP/AMP signals. GSH was predomi-
nant in SDHx- and VHL-related tumors.
Three-class model
A multivariate two-component PLS-DA based on succinate,
glutamate, GSH, and energy phosphorylated compounds (ATP/
ADP/AMP) was first generated including patients with apparently
sporadic, SDHx-, and VHL-related PGLs/PHEOs. The score plot
of the PLS-DA model (Fig. 3A) showed a clear distinction between
these three classes of tumors. According to this model, all 12
patients with SDHx-related PGLs/PHEOs were correctly identi-
fied. Moreover, eight of ten (80%) and five of six (83%) patients
with respectively apparently sporadic and VHL-related PGLs/
PHEOs were also accurately classified. To detect patients with
germline mutations (SDHx and VHL), the Se and Sp of the
established model were respectively 94% and 80%. PPV, NPV,
and global accuracy were all 89%.
In the SDHx-related tumor cohort, PHEOs exhibited higher
values of energy-phosphorylated compounds (ATP/ADP/AMP)
compared to PGLs (p = 0.04). Succinate, GSH, and glutamate
were statistically equivalent regardless of the SDHx tumor location.
In contrast, VHL-related PHEOs had higher GSH levels than
PGLs (p = 0.04). Considering all tissue samples, a significant
negative correlation was shown between succinate and glutamate
(R = 0.52), glutamate and energy phosphorylated compounds
(ATP/ADP/AMP) (R = 0.54), and succinate and GSH (R = 0.51).
Two-class models
Three multivariate PLS-DA models based on succinate,
glutamate, GSH, and energy phosphorylated compounds (ATP/
ADP/AMP) were built to compare: (1) apparently sporadic to
SDHx- (Fig. 3B), (2) apparently sporadic to VHL- (Fig. 3C), and (3)
SDHx- to VHL-related tumors (Fig. 3D). The score plot of each
PLS-DA model showed a very clear delineation of the single
classes. The results of the MWU-test are detailed in Table 1.
When comparing apparently sporadic to SDHx-related tumors,
the model correctly classified 9 of 10 apparently sporadic cases and
11 of 12 SDHx. The model identified SDHx-related tumors with a
Se of 92%, a Sp of 90%, a PPV of 92%, a NPV of 90%, and a
global accuracy of 91%. The model did not correctly identify only
one SDHD-related PGL. Interestingly, it was easily recognized by
visual inspection of the spectra because of a pronounced succinate
peak.
In the model comparing apparently sporadic and VHL-related
tumors, all cases were correctly classified. The VHL group
exhibited a significant increase in both succinate and GSH levels.
Finally, SDHx- and VHL-related PGLs/PHEOs were com-
pared. The model was able to correctly classify all the tumor
Metabolomics in PHEOs/PGLs
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samples. Succinate remains highly discriminant between the 2
subgroups. No difference in the succinate amount was shown
between SDHB and SDHD subtypes, as well as for the remaining
selected metabolites. VHL-related tumors showed a more
abundant content of energy phosphorylated compounds (ATP/
ADP/AMP). Interestingly, despite a greater amount of GSH in
VHL vs. SDHx tumors, this parameter did not reach statistical
significance (p = 0.08).
In apparently sporadic PGLs/PHEOs, glutamate and energy
phosphorylated compounds (ATP/ADP/AMP) (R = 0.71) as well
as succinate and GSH (R = 0.68) in SDHx-related tumors were
statistically correlated.
Epinephrine was not measurable in any VHL-related tumors
and in only one of 12 SDHx samples (1.98 nmol/ml). Only 2 of 10
apparently sporadic tumors showed an epinephrine peak in the
NMR spectra (0.93 and 1.04 nmol/ml). On the other hand,
norepinephrine was detected in 9 of 10 apparently sporadic
tumors (median, 0.90 nmol/ml; range, 0–4.60 nmol/ml), in 9 of
12 SDHx-related PHEOs/PGLs (median, 0.87 nmol/ml; range,
0–2.40 nmol/ml), and in all of the 6 VHL-related PHEOs/PGLs
(median, 1.80 nmol/ml; range, 0.26–4.53 nmol/ml). No statistical
difference was observed between VHL and SDHx PHEOs/PGLs
despite higher values of norepinephrine in VHL tumors.
Discussion
In the present study, we analyzed 28 sympathetic PGLs with
different genetic backgrounds (10 sporadic, 6 VHL, 12 SDHx). We
did not include RET- or NF1-related tumors because these are
almost always associated with other syndromic manifestations that
enable physicians to easily diagnose them.
In the present study we show that HRMAS NMR-based
metabolomics should be considered as a new reliable tool for ex vivo
characterization of sympathetic PGLs. The present data suggests
the existence of a specific succinate-glutamate hallmark of SDHx
sympathetic PGLs. Based on 4 metabolites (succinate, glutamate,
GSH, and ATP/ADP/AMP), tumors were accurately distin-
guished from the other ones on both 3- and 2-class PLS-DA
models. This is an extension of the results published by Rao et al.,
who identified an SDHx signature (increased succinate, decreased
ATP/ADP/AMP) but with some overlaps between apparently
sporadic and VHL tumors for the other parameters [17].
Until the present, only a few studies employing HRMAS NMR
spectroscopy have been published for metabolic profiling of
PGLs/PHEOs [17,24]. An increase in succinate accumulation and
a decrease in ATP/ADP/AMP accumulation were observed in
SDHx-related PGLs when compared to sporadic PGLs and PGLs
of other genotypes [17]. Interestingly, despite methodological
differences, we found similar results. Compared to the previous
study [17], in which liquid NMR spectroscopy was used to analyze
homogenized and centrifuged tissue preparation, our analysis was
done on intact tissue samples. This approach may be considered
less sensitive compared to liquid-state NMR spectroscopy but also
leads to good quality spectra. Furthermore, it has several
advantages, such as avoiding technical procedures for tissue
preparation prior to the analysis and allowing refreeze and storage
of tissue samples for additional analyzes such as pathological
analysis in cases of result discrepancies. Small changes (0.1 ppm) in
chemical shift in the peak areas assigned to the ATP/ADP/AMP
between the 2 studies could be attributed to pH differences
(perchloric acid extracts for Rao et al) [17].
Figure 1. Representative 1D 1H-HRMAS spectra of sporadic, SDHx-, and VHL-related PGLs. The partial metabolite assignment is indicated.
The metabolic contents of each spectra are directly comparable, since the intensity of each spectrum has been normalized with respect to the weight
of the analyzed sample.
doi:10.1371/journal.pone.0080539.g001
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We also found lower values of ATP/ADP/AMP in SDHx-
related tumors in comparison to VHL tumors, probably because
increased glycolysis preferentially occurs in VHL tumors [17,25].
We have added greater levels of discrimination by using
additional metabolites besides succinate and ATP/ADP/AMP
peaks. We found that apparently sporadic tumors were charac-
terized by a low level of reduced GSH compared to VHL tumors
(p = 0.01) and SDHx-related tumors (p = 0.003). There was a trend
towards statistical differences between SDHx- and VHL-related
tumors (p = 0.08), but the sample size was too small to achieve
statistical significance. GSH is the most prevalent non-protein thiol
in animal cells. Its high redox potential renders GSH both a potent
antioxidant and a convenient cofactor for enzymatic reactions that
require readily available electron pairs. GSH appears to be a
sensitive indicator of the ability to resist toxic challenge. It has
previously been shown that sporadic tumors may also exhibit
reduction of mitochondrial respiration [26]. The low GSH peak in
these tumors could be related to several cell events, such as
inhibition of the ETC that is needed for GSH regeneration via
NADPH synthesis and/or an increase in ROS production.
Interestingly, SDHx-related tumors were also characterized by
low glutamate levels in comparison to apparently sporadic
Figure 2. Representative 2D 1H-13C HSQC HRMAS NMR spectra (A), zoomed in on the ATP region (B), obtained from a sample of a
VHL-related abdominal PGL. The 2D NMR experiment confirms the presence of ATP in tumoral tissue as suggested by the 1D spectra of the same
patient (Figure 1C). Glutamate and norepinephrine assignments are also indicated. Because of their low concentration in the tissular sample, both
succinate and glutathione are not clearly visible in the whole 2D spectrum (7.7-0.7 ppm in 1H dimension) without focusing on their characteristic
regions.
doi:10.1371/journal.pone.0080539.g002
Figure 3. Results of two-component PLS-DA models built on succinate, glutamate, glutathione, and energy phosphorylated
compounds (ATP/ADP/AMP) according to the patients’ genotypes: A) 3-class model including apparently sporadic (black dots),
SDHx- (green dots), and VHL-related tumors (yellow dots); B) 2-class model including apparently sporadic and SDHx-related tumors;
C) 2-class model including apparently sporadic and VHL-related tumors; D) 2-class model including SDHx- and VHL-related tumors.
A clear distinction between the different classes of tumors is shown in each model.
doi:10.1371/journal.pone.0080539.g003
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(p = 0.003) and VHL tumors (p = 0.0007). This finding is new and
provides critical information for accurate classification of tumors.
Intracellular glutamate is mainly produced by the oxidative
deamination of glutamine. Interestingly, IDH1/2 mutant cells
are also characterized by lower levels of glutamate with respect to
their wild type counterparts [27]. It is also possible that lower
glutamate availability in SDHx-deficient tumors leads to the
generation of perooxidant conditions that promote carcinogenesis.
There is no clear explanation for the low glutamate level in SDHx-
related tumors in comparison to other subtypes. It could be related
to increased consumption of glutamate for further biosynthetic
pathways or decreased glutamate biosynthesis via modulation of
the activity of glutaminase or glutamate dehydrogenase.
In contrast, increased GSH levels in VHL-tumors may be
related to increased activity of the pentose phosphate pathway in
response to enhanced oxidative stress.
Our 3-class model enabled us to accurately predict the presence
of SDHx or VHL germline mutations with the following
performances: Se 94%, Sp 80%, and PPV/NPV 89%. The
presence of a succinate peak alone easily distinguishes SDHx-
related tumors from the other ones. The 2-class model based on
succinate/GSH could be used to distinguish VHL from apparently
sporadic tumors (global accuracy of 100%). Although our results
are promising, they should be validated in a large sample size and
independent cohort. This would help build a reliable probability
predictive model that may be used in clinics to guide genetic
testing and provide functional information about mutations of
equivocal pathogenicity (uncertain variants).
Immunohistochemical studies can also be used as a screening
method for guiding genetic testing. The absence of SDHB
immunoexpression is indicative of a germline mutation in one of
the SDHx genes [28,29]. Additionally, a subset of these tumors
may also be immunohistochemically negative for SDHA, which is
highly suggestive of the presence of an SDHA mutation [30].
Compared to other methods, metabolomic approaches provide
several practical advantages, such as the simplicity of sample
preparation, reproducibility, low cost for sample analysis, and
simultaneous measurement of several metabolites. Thus, they may
enable global metabolomic profiling of tumors with a distinction of
different tumor subtypes. Metabotyping various tumors, including
PGLs, might indeed identify new oncometabolites for their future
diagnostic and therapeutic options.
The present study further supports the existence of different
secretory phenotypes in PGLs according to their hereditary
background. In our series, epinephrine was not measurable in
any VHL-related tumors and in only one of the 12 SDHx samples.
By contrast, norepinephrine was detected in 9 out of 12 SDHx-
related tumors and in all of the 6 examined VHL-related PHEOs/
PGLs. The lack of epinephrine secretion in VHL- and SDHx-
related PGLs was previously reported [31–33] and linked to
reduced or absent expression of phenylethanolamine-N-methyl-
transferase (PNMT). PNMT catalyzes the last step in catechol-
amine biosynthesis, the conversion of norepinephrine to epineph-
rine. SDHx-related tumors exhibit an immature catecholamine
secretory profile by the absence of epinephrine, possibly explained
by hypermethylation of the PMNT promoter [34]. These tumors
accumulate succinate, which inhibits 2-oxoglutarate-dependent
histone and DNA demethylase enzymes, resulting in epigenetic
modifications [8]. These findings further emphasize the interplay
between the Krebs cycle, oxidative phosphorylation, and epige-
netic events [35,36].
We acknowledge several limitations to the present study: a) the
absence of carriers of mutations in the TMEM127/SDHAF2/
MAX/SDHA genes; and b) the absence of screening of tumors for
somatic mutations, mainly in apparently sporadic tumors, that
could potentially occur and influence the presented tumor
metabolomic profiles. We also have to admit that the high
proportion of hereditary PGLs in our series is related to a selection
bias. Nevertheless, the present study provides new data about
specific genotype-metabolomic phenotype of SDHx-related PGLs
compared to VHL-related and apparently sporadic counterparts.
The present study advances our knowledge of the pathogenesis
of PGLs and also provides important and promising information
about the classification of these tumors. It is expected that in the
near future, various metabolomic approaches will reveal new
diagnostic and therapeutic targets. A large-scale study comparing
PGL clinical and imaging phenotypes, genotypes, somatic
mutations, gene expression levels, DNA methylation phenotypes,
protein spectra, and metabolomic profiles will have a great impact
on our understanding of how they function and contribute to the
development of various PGLs, resulting in the most optimal early
and accurate diagnosis, treatment, and outcome.
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Table 1. Median values and ranges of succinate, glutathione, glutamate, and ATP/ADP/AMP levels measured by 1D 1H-HRMAS
spectroscopy in intact tissue samples of 28 apparently sporadic, SDHx, and VHL-related PHEOs/PGLs. Quantification results are
expressed as nmol/mg of tissue.
Sporadic SDHx VHL
P Sporadic vs
SDHx
P Sporadic vs
VHL P SDHx vs VHL
Succinate 0.03 (0–0.06) 3,6 (0.9–9.07) 0.06 (0.03–0.12) 0.000003 0.02 0.0001
Glutathione 0.04 (0.03–0.22) 0.15 (0.05–0.39) 0.32 (0.17–0.43) 0.01 0.003 0.08
Glutamate 1.36 (0.23–2.55) 0.67 (0.13–1.52) 1.49 (0.88–2.18) 0.003 1 0.0007
ATP/ADP/AMP 0.10 (0.03–0.18) 0.05 (0–0.21) 0.16 (0.06–0.29) 0.1 0.1 0.01
doi:10.1371/journal.pone.0080539.t001
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